Express Scripts Holding Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Express Scripts Holding Company
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Congressional Pressure Mounts On PBMs, But Skepticism Remains About Near-Term Action
Attention on PBMs with minimal risk of policy change may represent the best of both worlds for pharma, which benefits from another part of the industry taking the heat on drug prices but could stand to lose out financially depending on the PBM reform approaches taken.
Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.
CMS ‘Safe Harbor’ For Use Of Copay Accumulators In Private Insurance Challenged In Court
Patient groups ‘left with no choice’ but to challenge federal regulation allowing commercial payers to bar manufacturer assistance with drug costs from being counted toward deductibles and out-of-pocket spending caps.
- Pharmacy Services, PBMs
- Other Names / Subsidiaries
- Aristotle Holding, Inc.
- Cigna Corporation
- Express Scripts, Inc.
- Medco Health Solutions, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.